For the quarter ended June 2024, Travere Therapeutics (TVTX) reported revenue of $54.12 million, down 9.4% over the same period last year. EPS came in at -$0.90, compared to -$1.13 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $49.5 million, representing a surprise of +9.33%. The company delivered an EPS surprise of -3.45%, with the consensus EPS estimate being -$0.87. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings ...